Nancy J Donovan1, Olivia I Okereke2, Patrizia Vannini3, Rebecca E Amariglio4, Dorene M Rentz5, Gad A Marshall4, Keith A Johnson6, Reisa A Sperling4. 1. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston. 2. Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston. 5. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston. 6. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston6Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract
IMPORTANCE: Emotional and behavioral symptoms in cognitively normal older people may be direct manifestations of Alzheimer disease (AD) pathophysiology at the preclinical stage, prior to the onset of mild cognitive impairment. Loneliness is a perceived state of social and emotional isolation that has been associated with cognitive and functional decline and an increased risk of incident AD dementia. We hypothesized that loneliness might occur in association with elevated cortical amyloid burden, an in vivo research biomarker of AD. OBJECTIVE: To determine whether cortical amyloid burden is associated with greater loneliness in cognitively normal older adults. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analyses using data from the Harvard Aging Brain Study of 79 cognitively normal, community-dwelling participants. A continuous, aggregate measure of cortical amyloid burden, determined by Pittsburgh Compound B-positron emission tomography (PiB-PET), was examined in association with loneliness in linear regression models adjusting for age, sex, apolipoprotein E ε4 (APOEε4), socioeconomic status, depression, anxiety, and social network (without and with the interaction of amyloid and APOEε4). We also quantified the association of high amyloid burden (amyloid-positive group) to loneliness (lonely group) using logistic regression, controlling for the same covariates, with the amyloid-positive group and the lonely group, each composing 32% of the sample (n = 25). MAIN OUTCOMES AND MEASURES: Loneliness, as determined by the 3-item UCLA Loneliness Scale (possible range, 3-12, with higher score indicating greater loneliness). RESULTS: The 79 participants included 43 women and 36 men with a mean (SD) age of 76.4 (6.2) years. Mean (SD) cortical amyloid burden via PiB-PET was 1.230 (0.209), and the mean (SD) UCLA-3 loneliness score was 5.3 (1.8). Twenty-two (28%) had positive APOEε4 carrier status, and 25 (32%) were in the amyloid-positive group with cortical PiB distribution volume ratio greater than 1.2. Controlling for age, sex, APOEε4, socioeconomic status, depression, anxiety, and social network, we found that higher amyloid burden was significantly associated with greater loneliness: compared with individuals in the amyloid-negative group, those in the amyloid-positive group were 7.5-fold (95% CI, 1.7-fold to 34.0-fold) more likely to be classified as lonely than nonlonely (β = 3.3, partial r = 0.4, P = .002). Furthermore, the association of high amyloid burden and loneliness was stronger in APOEε4 carriers than in noncarriers. CONCLUSIONS AND RELEVANCE: We report a novel association of loneliness with cortical amyloid burden in cognitively normal older adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD. This work will inform new research into the neural underpinnings and disease mechanisms involved in loneliness and may enhance early detection and intervention research in AD.
IMPORTANCE: Emotional and behavioral symptoms in cognitively normal older people may be direct manifestations of Alzheimer disease (AD) pathophysiology at the preclinical stage, prior to the onset of mild cognitive impairment. Loneliness is a perceived state of social and emotional isolation that has been associated with cognitive and functional decline and an increased risk of incident AD dementia. We hypothesized that loneliness might occur in association with elevated cortical amyloid burden, an in vivo research biomarker of AD. OBJECTIVE: To determine whether cortical amyloid burden is associated with greater loneliness in cognitively normal older adults. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analyses using data from the Harvard Aging Brain Study of 79 cognitively normal, community-dwelling participants. A continuous, aggregate measure of cortical amyloid burden, determined by Pittsburgh Compound B-positron emission tomography (PiB-PET), was examined in association with loneliness in linear regression models adjusting for age, sex, apolipoprotein E ε4 (APOEε4), socioeconomic status, depression, anxiety, and social network (without and with the interaction of amyloid and APOEε4). We also quantified the association of high amyloid burden (amyloid-positive group) to loneliness (lonely group) using logistic regression, controlling for the same covariates, with the amyloid-positive group and the lonely group, each composing 32% of the sample (n = 25). MAIN OUTCOMES AND MEASURES: Loneliness, as determined by the 3-item UCLA Loneliness Scale (possible range, 3-12, with higher score indicating greater loneliness). RESULTS: The 79 participants included 43 women and 36 men with a mean (SD) age of 76.4 (6.2) years. Mean (SD) cortical amyloid burden via PiB-PET was 1.230 (0.209), and the mean (SD) UCLA-3 loneliness score was 5.3 (1.8). Twenty-two (28%) had positive APOEε4 carrier status, and 25 (32%) were in the amyloid-positive group with cortical PiB distribution volume ratio greater than 1.2. Controlling for age, sex, APOEε4, socioeconomic status, depression, anxiety, and social network, we found that higher amyloid burden was significantly associated with greater loneliness: compared with individuals in the amyloid-negative group, those in the amyloid-positive group were 7.5-fold (95% CI, 1.7-fold to 34.0-fold) more likely to be classified as lonely than nonlonely (β = 3.3, partial r = 0.4, P = .002). Furthermore, the association of high amyloid burden and loneliness was stronger in APOEε4 carriers than in noncarriers. CONCLUSIONS AND RELEVANCE: We report a novel association of loneliness with cortical amyloid burden in cognitively normal older adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD. This work will inform new research into the neural underpinnings and disease mechanisms involved in loneliness and may enhance early detection and intervention research in AD.
Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Cyrus A Raji; James T Becker; Nicholas D Tsopelas; Julie C Price; Chester A Mathis; Judith A Saxton; Brian J Lopresti; Jessica A Hoge; Scott K Ziolko; Steven T DeKosky; William E Klunk Journal: J Neurosci Methods Date: 2008-05-16 Impact factor: 2.390
Authors: Dorene M Rentz; Rebecca E Amariglio; J Alex Becker; Meghan Frey; Lauren E Olson; Katherine Frishe; Jeremy Carmasin; Jacqueline E Maye; Keith A Johnson; Reisa A Sperling Journal: Neuropsychologia Date: 2011-06-12 Impact factor: 3.139
Authors: J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Martina Luchetti; Antonio Terracciano; Damaris Aschwanden; Ji H Lee; Yannick Stephan; Angelina R Sutin Journal: Int J Geriatr Psychiatry Date: 2020-05-04 Impact factor: 3.485
Authors: P Aisen; J Touchon; R Amariglio; S Andrieu; R Bateman; J Breitner; M Donohue; B Dunn; R Doody; N Fox; S Gauthier; M Grundman; S Hendrix; C Ho; M Isaac; R Raman; P Rosenberg; R Schindler; L Schneider; R Sperling; P Tariot; K Welsh-Bohmer; M Weiner; B Vellas Journal: J Prev Alzheimers Dis Date: 2017
Authors: Nancy J Donovan; Joseph J Locascio; Gad A Marshall; Jennifer Gatchel; Bernard J Hanseeuw; Dorene M Rentz; Keith A Johnson; Reisa A Sperling Journal: Am J Psychiatry Date: 2018-01-12 Impact factor: 18.112
Authors: Kelsey D Biddle; Federico d'Oleire Uquillas; Heidi I L Jacobs; Benjamin Zide; Dylan R Kirn; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Nancy J Donovan Journal: Am J Geriatr Psychiatry Date: 2019-05-10 Impact factor: 4.105
Authors: Atiqul Haq Mazumder; Jennifer Barnett; Nina Lindberg; Minna Torniainen-Holm; Markku Lähteenvuo; Kaisla Lahdensuo; Martta Kerkelä; Jarmo Hietala; Erkki Tapio Isometsä; Olli Kampman; Tuula Kieseppä; Tuomas Jukuri; Katja Häkkinen; Erik Cederlöf; Willehard Haaki; Risto Kajanne; Asko Wegelius; Teemu Männynsalo; Jussi Niemi-Pynttäri; Kimmo Suokas; Jouko Lönnqvist; Solja Niemelä; Jari Tiihonen; Tiina Paunio; Aarno Palotie; Jaana Suvisaari; Juha Veijola Journal: Brain Sci Date: 2021-05-23
Authors: Jeffrey A Lam; Emily R Murray; Kasey E Yu; Marina Ramsey; Tanya T Nguyen; Jyoti Mishra; Brian Martis; Michael L Thomas; Ellen E Lee Journal: Neuropsychopharmacology Date: 2021-07-06 Impact factor: 7.853
Authors: Eider M Arenaza-Urquijo; Gemma Salvadó; Gregory Operto; Carolina Minguillón; Gonzalo Sánchez-Benavides; Marta Crous-Bou; Oriol Grau-Rivera; Aleix Sala-Vila; Carles Falcón; Marc Suárez-Calvet; Henrik Zetterberg; Kaj Blennow; Juan Domingo Gispert; José Luis Molinuevo Journal: Neurology Date: 2020-07-31 Impact factor: 9.910